As part of the agreement, Ranbaxy along with its partners Cipher Pharm and Galephar Pharma, has entered into a non-exclusive license agreement with Actavis under the Dublin-headquartered company may start selling its generic version of Absorica in the US on 27 December 2020 (nine months before the expiration of the patents in September 2021) or...